Celltrion Launches Higher-Strength Yuflyma Adalimumab In Canada

Public And Private Listings For Reimbursement Are In The Works

Months after it received approval from local regulator Health Canada, Celltrion’s Yuflyma high-concentration adalimumab biosimilar is now available in the North American market, setting up a potential rivalry with Alvotech and its marketing partner JAMP Pharma.

launch
Health Canada approval was received on Christmas Eve 2021 • Source: Alamy

Celltrion’s Canadian subsidiary has launched its Yuflyma (adalimumab) 100mg/ml biosimilar version of AbbVie’s higher-strength Humira following a landmark first approval several months ago.

A positive letter of intent has been received by Celltrion from the pan-Canadian Pharmaceutical Alliance, which groups federal and...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Products

More from Generics Bulletin